Clinical Studies of Progeria - Full Text View

Purpose

This study will examine children with Hutchinson-Gilford Progeria syndrome, a genetic disease that causes many changes to the body over time, including heart disease, bone changes, hair loss, and joint and skin changes. Often called a "premature aging" disease, progeria does not mimic aging completely. This study will examine which body systems are affected in progeria and how each system is affected over time in order to try to develop new treatments.

Patients with progeria who are between 6 months and 70 years of age and who are able to travel to the NIH in Bethesda, Md., may be eligible for this 5- to 10-year study.

Participants come to the NIH Clinical Center for evaluation every 2 years. Each 4-5 day visit includes the following tests and procedures:

Medical history and physical examination
Blood tests to analyze cardiovascular risk factors, blood counts, blood chemistries, and for research
Urine tests for sugar and proteins
Photographs to study growth problems
X-ray studies to determine bone density and body composition, such as body fat and muscle
Electrocardiogram (EKG) and echocardiogram (heart ultrasound) to study the heart and blood vessels
Lung function tests to measure energy consumption and lung capacity
Skin biopsy (surgical removal of a small skin sample) to examine cellular changes
Hearing tests
Eye examination to evaluate eyesight, eye pressure and structures of the eye
Physical therapy evaluation with stretching and exercises to measure how the joints bend and straighten
Dental examination, including X-rays
Meeting with a nutritionist who will track the patient's food intake and take body measurements
Magnetic resonance imaging (MRI) for patients who are old enough to undergo the procedure without sedation. This test uses a magnetic field and radio waves to examine body organs. For this test, the patient must lie still in the scanner, a narrow cylindrical tube.

Patients are provided the results of their medical tests. Information about the patient is submitted to the PRF Cell and Tissue Bank in Peabody, Massachusetts.

Condition
Progeria


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Retrospective
Official Title:	Clinical Investigations Into Hutchison-Gilford Progeria Syndrome

Resource links provided by NLM:

Genetics Home Reference related topics: Hutchinson-Gilford progeria syndrome

Genetic and Rare Diseases Information Center resources: Progeria

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):


Enrollment:	15
Study Start Date:	October 12, 2004

Detailed Description:

Hutchison-Gilford Progeria Syndrome (HGPS) is a rare "premature aging" disease in which children die of severe atherosclerosis at an average age of thirteen years (range 8-20 years). Children with HGPS appear healthy at birth, but within months display signs of growth failure, lipodystrophy, hair loss, and aged skin. Within just a few years they exhibit boney abnormalities including osteoporosis and resorption, coax valga and hip dislocation. The final height approximates 3 feet. Mortality is caused by generalized artherosclerosis leading to strokes and heart attacks. The gene defect causing HGPS has recently been identified as a single base mutation in the gene LMNA, coding for the nuclear protein Lamin A. The spectrum of effects of this gene defect on cellular function, and how these effects culminate in the HGPS disease phenotype, remain to be elucidated. Furthermore, no in-patient multisubject clinical evaluation of children with HGPS has ever been performed, and no therapy exists for any of the complications of HGPS. Hence, baseline studies are critical to determine the extent of organ involvement in HGPS, evaluate disease progression, and design clinical trials of potential treatments. The purpose of this study is to longitudinally investigate the disease characteristics of HGPS using state-of the-art measures of cardiovascular function, comprehensive laboratory testing, in vitro cell culture studies, and extensive medical consultations. HGPS patients will be admitted to the NIH Clinical center as inpatients for approximately 5 days every two years. The information emanating from the proposed studies will assist in assuring appropriate care for children with HGPS, provide a better understanding of the variations in phenotype of HGPS, and stimulate new research into HGPS and the aging diseases associated with HGPS, such as atherosclerosis. These studies will also allow us to evaluate new clinical outcome parameters and to design appropriate therapeutic interventions.

Eligibility


Ages Eligible for Study:	6 Months to 70 Years (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:
Inclusion criteria consist of male and female children of all ethnic groups with the diagnosis of HGPS.
An individual in whom a clinical diagnosis of HGPS has been

verified by Dr. Gordon will be eligible for this protocol.

EXCLUSION CRITERIA:

- Exclusion criteria consist of patients below 6 months and over 70 years of age. Another exclusion is the inability to travel to the NIH due to advanced cardiovascular disease, as reflected by unstable angina, congestive heart failure, or other serious symptoms.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00094393

Locations


United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Human Genome Research Institute (NHGRI)

Investigators


Principal Investigator:	William A Gahl, M.D.	National Human Genome Research Institute (NHGRI)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

DeBusk FL. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr. 1972 Apr;80(4):697-724. Review.

Pesce K, Rothe MJ. The premature aging syndromes. Clin Dermatol. 1996 Mar-Apr;14(2):161-70. Review.

Badame AJ. Progeria. Arch Dermatol. 1989 Apr;125(4):540-4. Review.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 7;358(6):592-604. doi: 10.1056/NEJMoa0706898.


Responsible Party:	National Human Genome Research Institute (NHGRI)
ClinicalTrials.gov Identifier:	NCT00094393 History of Changes
Other Study ID Numbers:	050004 05-HG-0004
Study First Received:	October 16, 2004
Last Updated:	April 21, 2017

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):


Ageing Atherosclerosis Lamin A Lipodystrophy	Growth Impairment Premature Aging Hutchinson-Gilford Progeria Syndrome HGPS

Additional relevant MeSH terms:


Progeria Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases

ClinicalTrials.gov processed this record on May 25, 2017